GenScript Unveils Prime Editing Boost with the Broad Institute Deal

PISCATAWAY, N.J., March 19, 2025 /PRNewswire/ -- GenScript Biotech Corp., a global biotechnology leader in life science, biologics manufacturing, synthetic biology, and cell therapies, announced an exciting investment in gene editing technology. GenScript has signed a licensing agreement with the Broad Institute of MIT to access Broad's Prime Editing technology. 

"This partnership with the Broad Institute marks an exhilarating new chapter for GenScript Life Science. For years, we have been deeply passionate about the extraordinary strides and transformative potential of gene editing. We see great potential for prime editing, and we're excited to contribute to the scientific community's evaluation of this technology." said Dr. Ray Chen, President of the Life Science Group at GenScript. 

This agreement permits GenScript to manufacture and commercialize prime editing components, including nucleases and customized synthetic guides, for other biopharma companies engaged in preclinical therapeutic R&D. This license will offer these companies a stable IP path when assessing prime editing technology. These companies will also benefit from GenScript's extensive experience in long (>250 bases) RNA synthesis, dedicated design tools, and, initially, 15 off-the-shelf nucleases and guides ready for testing.

Prime Editing, a more precise alternative to CRISPR/Cas9 that avoids DNA double-stranded breaks, has been rapidly advancing, fueled by research and therapeutic innovations. Prime Medicine announced yesterday a pre-clinical program for alpha-1 antitrypsin deficiency using this technology, complementing other initiatives like their Ex vivo CAR-T program with Bristol Myers Squibb.

For more information, please visit: www.genscript.com

Media Contact:

Michelle Simayi
Phone: 7324272987
Email: Michelle.Simayi@genscript.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genscript-unveils-prime-editing-boost-with-the-broad-institute-deal-302405978.html

SOURCE GenScript Biotech Corporation